[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335904-105":59,"doc-detail-335904-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","characteristics-and-survival-outcomes-of-patients-with-metastatic-ret-fusionpositive-solid-tumors-receiving-non-ret-inhibitor-standards-of-care-in-a-real-world-setting","Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion–Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting","","RET fusions act as oncogenic drivers across multiple solid tumors, yet patients’ genomic landscape and clinical course in real-world practice are insufficiently characterized. This study examines RET tyrosine kinase inhibitor (TKI)-naïve metastatic solid-tumor patients with RET fusion positivity (excluding non–small-cell lung cancer) and evaluates prognostic effects versus matched RET wild-type tumors. Real-world clinicogenomic data from routine comprehensive genomic profiling were analyzed to compare overall survival across matched cohorts.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/characteristics-and-survival-outcomes-of-patients-with-metastatic-ret-fusionpositive-solid-tumors-receiving-non-ret-inhibitor-standards-of-care-in-a-real-world-setting/335904/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/characteristics-and-survival-outcomes-of-patients-with-metastatic-ret-fusionpositive-solid-tumors-receiving-non-ret-inhibitor-standards-of-care-in-a-real-world-setting/335904.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of the study?","Question",{"text":112,"@type":113},"To describe clinical characteristics of RET fusion–positive solid tumors in RET TKI–naïve patients (excluding NSCLC) treated in a real-world setting and to assess the prognostic effect of RET fusions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients selected and cohorts constructed?",{"text":117,"@type":113},"RET TKI–naïve metastatic solid-tumor patients (excluding NSCLC) with at least one Foundation Medicine comprehensive genomic profiling test from January 1, 2011 to March 31, 2022 were identified. Overall survival was compared between RET fusion–positive tumors and matched RET wild-type (RET-WT) tumors using covariate matching (4:1).",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings regarding survival?",{"text":121,"@type":113},"Median overall survival was consistently lower for patients with RET fusion–positive tumors than for those with RET-WT tumors across three different analyses, indicating worse prognosis associated with RET fusions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335904,1790198348,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Original Reports | Precision Medicine  \nCharacteristics and Survival Outcomes of Patients With Metastatic RET Fusion–Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting  \nAllan Hackshaw, MSc1; Otto Fajardo, PhD2 ; Urania Dafni, ScD3 ; Hans Gelderblom, MD, PhD4 ; Pilar Garrido, MD, PhD5; Salvatore Siena, MD6 ; Matthew H. Taylor, MD7 ; Walter Bordogna, PhD2; and Christos Nikolaidis, MD, PhD2   \nDOI [https://doi.org/10.1200/PO.23.00334](https://doi.org/10.1200/PO.23.00334)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | RET fusions are oncogenic drivers across different solid tumors. However, the genomic landscape and natural history of patients with RET fusion–positive solid tumors are not well known. We describe the clinical characteristics of RET tyrosine kinase inhibitor (TKI)-nave patients with RET fusion–positive solid tumors (excluding non–small-cell lung cancer [NSCLC]), treated in a realworld setting and assess the prognostic effect of RET fusions. |\n| METHODS | Data for RET TKI-nave patients with metastatic solid tumors (excluding NSCLC) who had ≥one Foundation Medicine comprehensive genomic proﬁling test (January 1, 2011-March 31, 2022) were obtained from a deidentiﬁed nationwide (US-based) clinicogenomic database. The primary objective of this study was to compare the overall survival (OS) of patients with RET fusion– positive tumors versus matched patients with RET wild-type (RET-WT) tumors. Patients with RET-WT solid tumors were matched (4:1) to patients with RET fusion–positive tumors on the basis of preselected covariates. |\n| RESULTS | The study population included 26 patients in the RET fusion–positive cohort, 7,220 patients in the RET-WT cohort (before matching), and 104 patients in the matched RET-WT cohort. Co-occurring genomic alterations were rare in the RET fusion–positive cohort. Median OS was consistently lower in patients with RET fusion–positive tumors versus those with RET-WT tumors, using three different analyses (hazard ratios, 2.0, 1.7, and 2.2) . |\n| CONCLUSION | These data suggest that RET fusions represent a negative prognostic factor inpatients with metastatic solid tumors and highlight the need for wider genomic testing and use of RET-speciﬁc TKIs that could improve patient outcomes. Our study also highlights the value of real-world data when studying rare cancers or cancers with rare genomic alterations. |\n\nAccepted November 6, 2023 Published January 25, 2024  \nJCO Precis Oncol 8:e2300334 © 2024 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nFusions ofthe rearranged during transfection (RET) gene are oncogenic drivers across a number of solid tumors.1-3 Treatment options for patients with RET-altered solid tumors were previously limited to multikinase inhibitors, but these can be associated with signiﬁcant toxicities and high rates of dose reduction/discontinuation, and there may also be limited efﬁcacy.1 ,4,5 Therefore, there is a need for better precision therapies that selectively target RET alterationsand anticipated resistance mechanisms.  \nTwo RET-speciﬁc tyrosine kinase inhibitors (TKIs), selpercatinib and pralsetinib, have demonstrated durable antitumor  \nactivity and manageable toxicity proﬁles and are approved for the treatment of advanced/metastatic RET fusion–positive non–small-cell lung cancer (NSCLC; both drugs in the United States and Europe), advanced/metastatic RET-altered thyroid cancer (both drugs in the United States; selpercatinibin Europe), and advanced/metastatic RET fusion–positive solid tumors (selpercatinib in the United States; neither in Europe).6-9  \nRET fusions, although rare,5 ,10,11 have been detected in a wide range of solid tumors.5,12 However, the genomic landscape and natural history of patients with RET fusion–positive tumors are not well documented. It is important to understand whether RET fusion–positive tumors behave  \n[ascopubs.org/","cbCaipdXCJMCJ2lH","https://ap.wps.com/l/cbCaipdXCJMCJ2lH","pdf",648998,12,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Context\n# Methods","[{\"question\":\"What is the main purpose of the study?\",\"answer\":\"To describe clinical characteristics of RET fusion–positive solid tumors in RET TKI–naïve patients (excluding NSCLC) treated in a real-world setting and to assess the prognostic effect of RET fusions.\"},{\"question\":\"How were patients selected and cohorts constructed?\",\"answer\":\"RET TKI–naïve metastatic solid-tumor patients (excluding NSCLC) with at least one Foundation Medicine comprehensive genomic profiling test from January 1, 2011 to March 31, 2022 were identified. Overall survival was compared between RET fusion–positive tumors and matched RET wild-type (RET-WT) tumors using covariate matching (4:1).\"},{\"question\":\"What were the key findings regarding survival?\",\"answer\":\"Median overall survival was consistently lower for patients with RET fusion–positive tumors than for those with RET-WT tumors across three different analyses, indicating worse prognosis associated with RET fusions.\"}]","Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion–Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting | PDF",1790012788]